Research programme: anti-matrix metalloproteinase monoclonal antibodies - KadmonAlternative Names: DX-2400; DX-2802; KD-014
Latest Information Update: 29 Jan 2016
At a glance
- Originator Dyax
- Developer Shire
- Class Monoclonal antibodies
- Mechanism of Action Matrix metalloproteinase 14 inhibitors; Matrix metalloproteinase 9 inhibitors; Matrix metalloproteinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer